MADRIGAL PHARMACEUTICALS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$958M
Cost of Revenue
$6M
R&D
$389M
SG&A
$814M
D&A
$2M
Operating Income
$-300M
EBITDA
$-299M
Interest Expense
$22M
Interest Income
$37M
Other Income/Expense
$127M
Pretax Income
$-159M
Tax Provision
$0
Net Income
$-288M
Operating Margin
-31.3%
Net Margin
-30.1%
Effective Tax Rate
0.0%
Deferred Tax Assets
$362K
Deferred Tax Liabilities
$245K
DTA Valuation Allowance
$591M
Tax Credit Carryforwards
$69M
NOL Carryforwards
$214M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
Operating Lease Cost
$2M
Revenue YoY Variation
432.1%
Income YoY Variation
39.7%